iConcept Press Logo
Email Password Remember me
Research on Immunology
Title
Research on Immunology
Editor
iConcept Press
Price
USD$39.00
ISBN
978-1-922227-91-1
Clicks
10834

Chapter 3

Research on Immunology

Synchronous DC/CIK and Thoracic Radiotherapy in Patients with Advanced NSCLC: An Open-label, Single-center, Phase II Study

by Lu-Ping Zhang, Jian-Guo Sun, Yan-Mei Xu, Jie Shen, Feng He, Dan Zhang and Zheng-Tang Chen

Viewed: 1109

Abstract

Background Dendritic cell (DC) vaccine combined with cytokine-induced killer cell (CIK) is an efficient way to elicit anti-tumor immune responses. How to maximize the therapeutic efficacy of DC/CIK cytotherapy in clinical work has been under consideration. Accumulating evidences show that thoracic radiotherapy (TRT) may promote anti-tumor immune effects of non-small cell lung cancer (NSCLC). There are few prospective studies on the clinical benefits of DC/CIK cytotherapy combined with TRT in patients with advanced NSCLC. Objective This study aimed to explore the efficacy, safety and immunologic effects of DC/CIK cytotherapy combined with TRT in patients with advanced NSCLC. Patients and Methods The eligibility criteria were as follows: pathologically diagnosed as unresectable stage III or IV advanced NSCLC; at least 18 years of age; a life expectancy of more than 3 months; performance status (PS) 0-2; adequate organ function; two or more cycles of previous chemotherapy and at least one measurable lesion. In control group, TRT alone was given at 2 Gy per fraction, 5 fractions per week to a total dose of 60-66 Gy. In treatment group, in addition to the TRT regimens mentioned above, patients received a weekly autologous DC injection for four successive weeks starting from the 6th fraction of irradiation, and CIK infusion for four continuous days from day 11. The primary endpoint for this study was median progression-free survival (mPFS), and secondary endpoints were objective response rate (ORR), disease control rate (DCR), median overall survival (mOS), PS changes and side effects. Immunologic effects were to be explored. This clinical trial was registered at Chinese Clinical Trial Registry (ChiCTR-TRC-12002369, http://www.chictr.org/en/) and approved by the Ethics Committee of General Logistics Department of PLA, China. Results Eighty-two patients with advanced NSCLC were enrolled in this study, with 21 in treatment group and 61 in control group. There was no significant difference in the gender, age, clinical stage and the total dose of radiotherapy between the two groups (P > 0.05). The mPFS was longer in treatment group than in control group (330 days vs. 233 days, hazard ratio 0.51, 95% CI 0.27-1.0, P < 0.05), and the ORR in treatment group (47.6%) was significantly higher than that in control group (24.6%, P < 0.05). There was no significant difference in DCR and mOS between the two groups (P > 0.05). The side effects in treatment group were mild and there were no any treatment-related deaths. Conclusion DC/CIK cytotherapy combined with TRT had a higher response rate and a more significant improvement in PFS than TRT alone in patients with locally advanced or metastatic NSCLC.

Author Details

Lu-Ping Zhang
Cancer Institute of PLA, Xinqiao Hospital, Chongqing, China
Jian-Guo Sun
Third Military Medical University, Chongqing, China
Yan-Mei Xu
Oncology Department, Leshan People’s Hospital, Chongqing, China
Jie Shen
Third Military Medical University, Chongqing, China
Feng He
Third Military Medical University, Chongqing, China
Dan Zhang
Cancer Institute of People's Liberation Army, Xinqiao Hospital, Third Military Medical University, Third Military Medical University, Chongqing, China
Zheng-Tang Chen
Third Military Medical University, Chongqing, China

Citation

Lu-Ping Zhang, Jian-Guo Sun, Yan-Mei Xu, Jie Shen, Feng He, Dan Zhang and Zheng-Tang Chen. Synchronous DC/CIK and Thoracic Radiotherapy in Patients with Advanced NSCLC: An Open-label, Single-center, Phase II Study. In Research on Immunology. ISBN:978-1-922227-91-1. iConcept Press. 2016.

Download